Literature DB >> 31821430

Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry.

Scott M Damrauer1,2, Kumardeep Chaudhary3,4,5, Judy H Cho3,4,5,6, Lusha W Liang7, Edgar Argulian8, Lili Chan3,4,6, Amanda Dobbyn3,4,5, Marie A Guerraty9, Renae Judy1, Jenna Kay9, Rachel L Kember10,11, Michael G Levin9, Aparna Saha3,4, Tielman Van Vleck3,4, Shefali S Verma10, JoEllen Weaver12, Noura S Abul-Husn3,5,6,13, Aris Baras14, Julio A Chirinos9, Brian Drachman9, Eimear E Kenny3,5,13, Ruth J F Loos3,15,16, Jagat Narula8, John Overton14, Jeffrey Reid14, Marylyn Ritchie10, Giorgio Sirugo17, Girish Nadkarni3,4,6, Daniel J Rader7,10,17, Ron Do3,4,5.   

Abstract

Importance: Hereditary transthyretin (TTR) amyloid cardiomyopathy (hATTR-CM) due to the TTR V122I variant is an autosomal-dominant disorder that causes heart failure in elderly individuals of African ancestry. The clinical associations of carrying the variant, its effect in other African ancestry populations including Hispanic/Latino individuals, and the rates of achieving a clinical diagnosis in carriers are unknown. Objective: To assess the association between the TTR V122I variant and heart failure and identify rates of hATTR-CM diagnosis among carriers with heart failure. Design, Setting, and Participants: Cross-sectional analysis of carriers and noncarriers of TTR V122I of African ancestry aged 50 years or older enrolled in the Penn Medicine Biobank between 2008 and 2017 using electronic health record data from 1996 to 2017. Case-control study in participants of African and Hispanic/Latino ancestry with and without heart failure in the Mount Sinai BioMe Biobank enrolled between 2007 and 2015 using electronic health record data from 2007 to 2018. Exposures: TTR V122I carrier status. Main Outcomes and Measures: The primary outcome was prevalent heart failure. The rate of diagnosis with hATTR-CM among TTR V122I carriers with heart failure was measured.
Results: The cross-sectional cohort included 3724 individuals of African ancestry with a median age of 64 years (interquartile range, 57-71); 1755 (47%) were male, 2896 (78%) had a diagnosis of hypertension, and 753 (20%) had a history of myocardial infarction or coronary revascularization. There were 116 TTR V122I carriers (3.1%); 1121 participants (30%) had heart failure. The case-control study consisted of 2307 individuals of African ancestry and 3663 Hispanic/Latino individuals; the median age was 73 years (interquartile range, 68-80), 2271 (38%) were male, 4709 (79%) had a diagnosis of hypertension, and 1008 (17%) had a history of myocardial infarction or coronary revascularization. There were 1376 cases of heart failure. TTR V122I was associated with higher rates of heart failure (cross-sectional cohort: n = 51/116 TTR V122I carriers [44%], n = 1070/3608 noncarriers [30%], adjusted odds ratio, 1.7 [95% CI, 1.2-2.4], P = .006; case-control study: n = 36/1376 heart failure cases [2.6%], n = 82/4594 controls [1.8%], adjusted odds ratio, 1.8 [95% CI, 1.2-2.7], P = .008). Ten of 92 TTR V122I carriers with heart failure (11%) were diagnosed as having hATTR-CM; the median time from onset of symptoms to clinical diagnosis was 3 years. Conclusions and Relevance: Among individuals of African or Hispanic/Latino ancestry enrolled in 2 academic medical center-based biobanks, the TTR V122I genetic variant was significantly associated with heart failure.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31821430      PMCID: PMC7081752          DOI: 10.1001/jama.2019.17935

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  27 in total

1.  Genetic Diversity and Association Studies in US Hispanic/Latino Populations: Applications in the Hispanic Community Health Study/Study of Latinos.

Authors:  Matthew P Conomos; Cecelia A Laurie; Adrienne M Stilp; Stephanie M Gogarten; Caitlin P McHugh; Sarah C Nelson; Tamar Sofer; Lindsay Fernández-Rhodes; Anne E Justice; Mariaelisa Graff; Kristin L Young; Amanda A Seyerle; Christy L Avery; Kent D Taylor; Jerome I Rotter; Gregory A Talavera; Martha L Daviglus; Sylvia Wassertheil-Smoller; Neil Schneiderman; Gerardo Heiss; Robert C Kaplan; Nora Franceschini; Alex P Reiner; John R Shaffer; R Graham Barr; Kathleen F Kerr; Sharon R Browning; Brian L Browning; Bruce S Weir; M Larissa Avilés-Santa; George J Papanicolaou; Thomas Lumley; Adam A Szpiro; Kari E North; Ken Rice; Timothy A Thornton; Cathy C Laurie
Journal:  Am J Hum Genet       Date:  2016-01-07       Impact factor: 11.025

2.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

3.  Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study.

Authors:  Frederick E Dewey; Michael F Murray; John D Overton; Lukas Habegger; Joseph B Leader; Samantha N Fetterolf; Colm O'Dushlaine; Cristopher V Van Hout; Jeffrey Staples; Claudia Gonzaga-Jauregui; Raghu Metpally; Sarah A Pendergrass; Monica A Giovanni; H Lester Kirchner; Suganthi Balasubramanian; Noura S Abul-Husn; Dustin N Hartzel; Daniel R Lavage; Korey A Kost; Jonathan S Packer; Alexander E Lopez; John Penn; Semanti Mukherjee; Nehal Gosalia; Manoj Kanagaraj; Alexander H Li; Lyndon J Mitnaul; Lance J Adams; Thomas N Person; Kavita Praveen; Anthony Marcketta; Matthew S Lebo; Christina A Austin-Tse; Heather M Mason-Suares; Shannon Bruse; Scott Mellis; Robert Phillips; Neil Stahl; Andrew Murphy; Aris Economides; Kimberly A Skelding; Christopher D Still; James R Elmore; Ingrid B Borecki; George D Yancopoulos; F Daniel Davis; William A Faucett; Omri Gottesman; Marylyn D Ritchie; Alan R Shuldiner; Jeffrey G Reid; David H Ledbetter; Aris Baras; David J Carey
Journal:  Science       Date:  2016-12-23       Impact factor: 47.728

Review 4.  Frequency and genetic background of the position 122 (Val----Ile) variant transthyretin gene in the black population.

Authors:  D R Jacobson; J D Reveille; J N Buxbaum
Journal:  Am J Hum Genet       Date:  1991-07       Impact factor: 11.025

5.  Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men.

Authors:  Daniel Jacobson; Clement Tagoe; Arthur Schwartzbard; Alan Shah; James Koziol; Joel Buxbaum
Journal:  Am J Cardiol       Date:  2011-05-19       Impact factor: 2.778

6.  The amyloidogenic V122I transthyretin variant in elderly black Americans.

Authors:  C Cristina Quarta; Joel N Buxbaum; Amil M Shah; Rodney H Falk; Brian Claggett; Dalane W Kitzman; Thomas H Mosley; Kenneth R Butler; Eric Boerwinkle; Scott D Solomon
Journal:  N Engl J Med       Date:  2015-01-01       Impact factor: 91.245

7.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

Authors:  Merrill D Benson; Márcia Waddington-Cruz; John L Berk; Michael Polydefkis; Peter J Dyck; Annabel K Wang; Violaine Planté-Bordeneuve; Fabio A Barroso; Giampaolo Merlini; Laura Obici; Morton Scheinberg; Thomas H Brannagan; William J Litchy; Carol Whelan; Brian M Drachman; David Adams; Stephen B Heitner; Isabel Conceição; Hartmut H Schmidt; Giuseppe Vita; Josep M Campistol; Josep Gamez; Peter D Gorevic; Edward Gane; Amil M Shah; Scott D Solomon; Brett P Monia; Steven G Hughes; T Jesse Kwoh; Bradley W McEvoy; Shiangtung W Jung; Brenda F Baker; Elizabeth J Ackermann; Morie A Gertz; Teresa Coelho
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

8.  Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).

Authors:  Mathew S Maurer; Mazen Hanna; Martha Grogan; Angela Dispenzieri; Ronald Witteles; Brian Drachman; Daniel P Judge; Daniel J Lenihan; Stephen S Gottlieb; Sanjiv J Shah; D Eric Steidley; Hector Ventura; Srinivas Murali; Marc A Silver; Daniel Jacoby; Savitri Fedson; Scott L Hummel; Arnt V Kristen; Thibaud Damy; Violaine Planté-Bordeneuve; Teresa Coelho; Rajiv Mundayat; Ole B Suhr; Márcia Waddington Cruz; Claudio Rapezzi
Journal:  J Am Coll Cardiol       Date:  2016-07-12       Impact factor: 24.094

9.  Second-generation PLINK: rising to the challenge of larger and richer datasets.

Authors:  Christopher C Chang; Carson C Chow; Laurent Cam Tellier; Shashaank Vattikuti; Shaun M Purcell; James J Lee
Journal:  Gigascience       Date:  2015-02-25       Impact factor: 6.524

10.  The genetic ancestry of African Americans, Latinos, and European Americans across the United States.

Authors:  Katarzyna Bryc; Eric Y Durand; J Michael Macpherson; David Reich; Joanna L Mountain
Journal:  Am J Hum Genet       Date:  2014-12-18       Impact factor: 11.025

View more
  27 in total

1.  Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis.

Authors:  Gabriela Spencer-Bonilla; Joyce N Njoroge; Keon Pearson; Ronald M Witteles; Mandar A Aras; Kevin M Alexander
Journal:  Curr Cardiovasc Risk Rep       Date:  2021-04-04

2.  Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population.

Authors:  Julia Kozlitina; Sonia Garg; Mark H Drazner; Susan A Matulevicius; Colby Ayers; John Overton; Jeffrey Reid; Aris Baras; Krishnasree Rao; Ambarish Pandey; Jarett Berry; James A de Lemos; Justin L Grodin
Journal:  J Card Fail       Date:  2021-10-09       Impact factor: 5.712

3.  Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review.

Authors:  Pranav Chandrashekar; Laith Alhuneafat; Meghan Mannello; Lana Al-Rashdan; Morris M Kim; Jason Dungu; Kevin Alexander; Ahmad Masri
Journal:  Circ Genom Precis Med       Date:  2021-08-31

4.  Understanding the Complexity of Heart Failure Risk and Treatment in Black Patients.

Authors:  Aditi Nayak; Albert J Hicks; Alanna A Morris
Journal:  Circ Heart Fail       Date:  2020-08-13       Impact factor: 8.790

Review 5.  Clinical approach to genetic testing in amyloid cardiomyopathy: from mechanism to effective therapies.

Authors:  Rabah Alreshq; Frederick L Ruberg
Journal:  Curr Opin Cardiol       Date:  2021-05-01       Impact factor: 2.161

Review 6.  Risk-Based Approach for the Prediction and Prevention of Heart Failure.

Authors:  Arjun Sinha; Deepak K Gupta; Clyde W Yancy; Sanjiv J Shah; Laura J Rasmussen-Torvik; Elizabeth M McNally; Philip Greenland; Donald M Lloyd-Jones; Sadiya S Khan
Journal:  Circ Heart Fail       Date:  2021-02-04       Impact factor: 8.790

Review 7.  Promise and Peril of Population Genomics for the Development of Genome-First Approaches in Mendelian Cardiovascular Disease.

Authors:  Victoria N Parikh
Journal:  Circ Genom Precis Med       Date:  2021-02-01

8.  Association of the V122I Transthyretin Amyloidosis Genetic Variant With Cardiac Structure and Function in Middle-aged Black Adults: Coronary Artery Risk Development in Young Adults (CARDIA) Study.

Authors:  Arjun Sinha; Yinan Zheng; Drew Nannini; Yishu Qu; Lifang Hou; Sanjiv J Shah; Clyde W Yancy; Elizabeth M McNally; Myriam Fornage; Joao Lima; Donald M Lloyd-Jones; Laura J Rasmussen-Torvik; Sadiya S Khan
Journal:  JAMA Cardiol       Date:  2020-12-23       Impact factor: 14.676

Review 9.  Multidisciplinary Approaches for Transthyretin Amyloidosis.

Authors:  Haruki Koike; Takahiro Okumura; Toyoaki Murohara; Masahisa Katsuno
Journal:  Cardiol Ther       Date:  2021-06-04

10.  Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease.

Authors:  Lili Chan; Girish N Nadkarni; Fergus Fleming; James R McCullough; Patricia Connolly; Gohar Mosoyan; Fadi El Salem; Michael W Kattan; Joseph A Vassalotti; Barbara Murphy; Michael J Donovan; Steven G Coca; Scott M Damrauer
Journal:  Diabetologia       Date:  2021-04-02       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.